Acute Graft-Versus-Host Disease Pipeline Report 2024 | Clinical Trials, FDA, EMA, PMDA Approvals, Drugs and Companies

DelveInsight's, "Acute Graft-versus-Host Disease Pipeline Insight, 2024," report provides comprehensive insights about 21+ companies and 23+ pipeline drugs in Acute Graft-versus-Host Disease pipeline landscape. It covers the Acute Graft-Versus-Host Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Acute Graft-Versus-Host Disease therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Acute Graft-Versus-Host Disease research. Learn more about our innovative pipeline today! @ Acute Graft-Versus-Host Disease Pipeline Outlook [https://www.delveinsight.com/sample-request/acute-graft-versus-host-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Acute Graft-Versus-Host Disease Pipeline Report

* June 2024:- Equillium- A Phase 3, Randomized, Double-Blind, Placebo-Controlled Multicenter Study of Itolizumab in Combination With Corticosteroids for the Initial Treatment of Acute Graft Versus Host Disease. This is a multi-center study to compare the efficacy and safety of itolizumab versus placebo as first-line therapy for subjects with Grade III-IV aGVHD or Grade II with LGI involvement, in combination with corticosteroids.
* June 2024:-Institut de Recherches Internationales Servier- Phase I / II, Open Label, Dose Escalation Part (Phase I) Followed by Non-comparative Expansion Part (Phase II), Multi-centre Study, Evaluating Safety, Pharmacokinetics and Efficacy of S65487, a Bcl2 Inhibitor Combined With Azacitidine in Adult Patients With Previously Untreated Acute Myeloid Leukemia Not Eligible for Intensive Treatment.
* June 2024:- M.D. Anderson Cancer Center - A Phase I-II Study Investigating the All Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE). Part 1b of this clinical research study is to find the highest tolerable dose of SNDX-5613 that can be given in combination with ASTX727 (a combination of the drugs decitabine/cedazuridine) and venetoclax for patients with acute myeloid leukemia (AML) or those with a mixed phenotype acute leukemia with a myeloid phenotype (MPAL).
* June 2024:- Novartis Pharmaceuticals - The purpose of this study is to study the effectiveness of implementation of a systematic LDL-C management pathway including treatment with inclisiran in participants who have experienced a recent acute coronary syndrome (ACS) and have an increased LDL-cholesterol ( greater than or equal to 70 mg/dL) despite being treated with a statin drug,
* DelveInsight's Acute Graft-Versus-Host Disease pipeline report depicts a robust space with 21+ active players working to develop 23+ pipeline therapies for Acute Graft-Versus-Host Disease treatment.
* The leading Acute Graft-Versus-Host Disease Companies such as MaaT Pharma, Medac, CSL Behring, Humanigen, Ironwood Pharmaceuticals, ReAlta Life Sciences, Roche, Incyte Corporation, and others.
* Promising Acute Graft-Versus-Host Disease Therapies such as Uvadex, ASC930, Jaktinib Hydrochloride Tablets, EQ001 , Abatacept, and others.

Stay informed about the cutting-edge advancements in Acute Graft-Versus-Host Disease treatments. Download for updates and be a part of the revolution in cancer care @ Acute Graft-Versus-Host Disease Clinical Trials Assessment [https://www.delveinsight.com/sample-request/acute-graft-versus-host-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Acute Graft-Versus-Host Disease Emerging Drugs Profile

* MaaT013: MaaT Pharma

MaaT Pharma is developing MaaT013, which is made up of allogeneic, full-ecosystem pooled biotherapeutic intestinal microbiota manufactured in France, per the GMP requirements. It is an off-the-shelf, standardized, pooled-donor, high-richness microbiome biotherapeutic in enema formulation. The product is characterized by a high diversity and consistent richness of microbial species. MaaT013 aims to restore the symbiotic relationship between the patient's functional gut microbiome and their immune system to correct the responsiveness and tolerance of immune functions and thus reduce steroid-resistant, gastrointestinal-predominant aGvHD. The drug is currently being evaluated under Phase III clinical trial for the treatment of Acute Graft-versus-Host Disease.

* Lenzilumab: Humanigen

Lenzilumab is a proprietary Humaneered first-in-class monoclonal antibody that has been proven to neutralize GM-CSF, a cytokine of critical importance in the hyperinflammatory cascade, sometimes referred to as cytokine release syndrome, or cytokine storm, associated with COVID-19 and other indications. Lenzilumab binds to and neutralizes GM-CSF, consequently improving outcomes for patients hospitalized with COVID-19. Humanigen believes that its GM-CSF neutralization has the potential to reduce the hyper-inflammatory cascade known as cytokine release syndrome common to chimeric antigen receptor T-cell (CAR-T) therapy and aGvHD. The drug is currently being evaluated under Phase II/III clinical trial for the treatment of Acute Graft-versus-Host Disease.

* Apraglutide: Ironwood Pharmaceuticals

Apraglutide is an investigational new drug that is a next-generation, long-acting synthetic GLP-2 analog being developed for a range of rare gastrointestinal diseases where GLP-2 can play a central role in addressing disease pathophysiology, including short bowel syndrome with intestinal failure (SBS-IF) and Acute Graft-Versus-Host Disease (aGVHD). The drug is currently being evaluated under Phase II clinical trial for the treatment of Acute Graft-Versus-Host Disease (aGVHD).

Learn more about Acute Graft-Versus-Host Disease Drugs opportunities in our groundbreaking metastatic prostate cancer research and development projects @ Acute Graft-Versus-Host Disease Unmet Needs [https://www.delveinsight.com/sample-request/acute-graft-versus-host-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Acute Graft-versus-Host Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

* Intravenous
* Subcutaneous
* Oral
* Intramuscular

Acute Graft-Versus-Host Disease Products have been categorized under various Molecule types such as

* Monoclonal antibody
* Small molecule
* Peptide

Discover the latest advancements in Acute Graft-Versus-Host Disease treatment by visiting our website. Stay informed about how we're transforming the future of Immunological and Autoimmune Disorders @ Acute Graft-Versus-Host Disease Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/acute-graft-versus-host-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Acute Graft-Versus-Host Disease Pipeline Report

* Coverage- Global
* Acute Graft-Versus-Host Disease Companies- MaaT Pharma, Medac, CSL Behring, Humanigen, Ironwood Pharmaceuticals, ReAlta Life Sciences, Roche, Incyte Corporation, and others.
* Acute Graft-Versus-Host Disease Therapies- Uvadex, ASC930, Jaktinib Hydrochloride Tablets, EQ001, Abatacept, and others.
* Acute Graft-Versus-Host Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Acute Graft-Versus-Host Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Acute Graft-Versus-Host Disease pipeline on our website @ Acute Graft-Versus-Host Disease Emerging Drugs and Companies [https://www.delveinsight.com/sample-request/acute-graft-versus-host-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

* Introduction
* Executive Summary
* Acute Graft-versus-Host Disease: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Acute Graft-versus-Host Disease- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* MaaT013: MaaT Pharma
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Apraglutide: Ironwood Pharmaceuticals
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I/II)
* Drug name: Company name
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name: Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Acute Graft-versus-Host Disease Key Companies
* Acute Graft-versus-Host Disease Key Products
* Acute Graft-versus-Host Disease- Unmet Needs
* Acute Graft-versus-Host Disease- Market Drivers and Barriers
* Acute Graft-versus-Host Disease- Future Perspectives and Conclusion
* Acute Graft-versus-Host Disease Analyst Views
* Acute Graft-versus-Host Disease Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=acute-graftversushost-disease-pipeline-report-2024-clinical-trials-fda-ema-pmda-approvals-drugs-and-companies]
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services



This release was published on openPR.